Blood
Articles in this Issue
Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL
Abstract Introduction: CD19 directed CAR T cell therapies, such as axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel)...
Fludarabine, cyclophosphamide, and melphalan (FCM) preconditioning in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia: Update of a prospective, multicenter, single-arm clinical study
Abstract Background: Haematopoietic stem cell transplantation (HSCT) is a crucial treatment for severe aplastic anemia (SAA). However, there...
End-of-study analysis of the HOPE-B trial confirms the durable efficacy and safety of etranacogene dezaparvovec hemophilia b gene therapy over 5 years
Abstract Introduction: Etranacogene dezaparvovec, the first approved gene therapy for hemophilia B, is an adeno-associated virus serotype 5...
The actual usefulness of culturing apheresis products in hematopoietic stem cell autotransplants.
Abstract Background: Bacterial cultures of the apheresis products for autologous hematopoietic stem cell transplants (aHSCT) are mandatory i...
Pregnancy outcomes after crovalimab exposure: Analysis of animal model and clinical trial data suggest no adverse effects in paroxysmal nocturnal hemoglobinuria
Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening, complement-mediated hematologic disorder. Pregnan...
Impact of pre-existing psychiatric conditions on toxicity and outcomes of patients after BCMA-directed CAR-T cell therapy
Abstract Background: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are BCMA-directed CAR-T cell therapies appro...
Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study
Abstract Introduction Defining the epidemiology of myelodysplastic syndromes/neoplasms (MDS) and precursor conditions, such as clonal cytopen...
Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response
Abstract Background T-cell engaging bispecific antibodies (BsAbs) have shown promising activity in patients with relapse...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes
Abstract Background: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an underdiagnosed rare disease with poor outcomes and limited t...
The burden of myeloma treatment routes and locations on patients and families: Insights from a Pan-European survey
Abstract Introduction Myeloma patients may undergo multiple treatments over the course of their disease. Treatment speci...
Radiomic features from PET-CT enable diagnostic and prognostic stratification in peripheral T-cell lymphoma
Abstract Introduction Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphoma. While novel therapies are emerging,...
Interleukin-8 inhibition by reparixin protects megakaryocytes and alleviates thrombocytopenia in Acute Myeloid Leukemia
Abstract Introduction Hemorrhage is a frequent and potentially fatal complication of acute myeloid leukemia (AML) that largely reflects disor...
Deficiency of MRPL57 in acute myeloid leukemia patients leads to suboptimal therapeutic outcomes with CAR-T cell therapy
Abstract Background: CAR-T cells therapy has achieved breakthrough success in acute lymphoblastic leukemia (ALL), but its efficacy remains p...
Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy
Abstract Background Patients with relapsed/refractory multiple myeloma (R/R MM) receiving chimeric antigen receptor (CAR) T-cell therapy are...
Selective PAR1 activation mitigates pain and neuroinflammatory markers in a murine model of sickle cell disease
Abstract Acute pain is the most common and debilitating symptom of sickle cell disease (SCD), with recurrent vaso-occlusive episodes being t...
Long-term update on safety and efficacy of low-dose post-transplant cyclophosphamide in the HLA-mismatched unrelated transplant setting
Abstract Introduction The application of post-transplant cyclophosphamide (PTCy), as GvHD prophylaxis, has been increasingly used in matched...
Infections following combined therapy with a GPRC5DxCD3 bispecific antibody, talquetamab, and an interleukin-6 receptor inhibitor, tocilizumab, in multiple myeloma patients
Abstract Background The treatment landscape for multiple myeloma has been significantly advanced by the FDA-approval of talquetamab, a GPRC5D...
Mapping the past, predicting the future: Hematologic malignancy mortality trends (1968–2023) and forecasts through 2050 in older u.S adults
Abstract Introduction: Hematological malignancies remain a leading cause of cancer-related deaths among adults aged ≥65 years. Understanding...
Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial
Abstract Background Elranatamab (ELRA), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, induced deep and durable responses with...
Exposure to agent orange and risk of myelodysplastic syndromes
Abstract Background Myelodysplastic syndromes (MDS) develop from the acquisition of somatic mutations over years or decades. While some muta...
Survival and clinical response to bortezomib, thalidomide, and dexamethasone in patients with multiple myeloma at a peruvian tertiary care center: A real-world retrospective observational study
Abstract Introduction Multiple myeloma (MM) is an incurable hematologic malignancy characterized by the clonal proliferation of plasma cells...
Pharmacokinetic failure of obinutuzumab due to massive third-space sequestration in a patient with high-burden follicular lymphoma: A rationale for therapeutic drug monitoring and dose intensification
Abstract Background: Obinutuzumab is a cornerstone therapy for B-cell non-Hodgkin lymphomas (B-NHL). While high tumor burden (quantified as...
Venous thromboembolism in multiple myeloma: A nationwide analysis of risk factors, mortality, and disparities
Abstract Background Venous thromboembolism (VTE) contributes substantially to morbidity and mortality in individuals wit...
Impact of the duffy-null phenotype on hydroxyurea dosing and clinical outcomes in children with sickle cell disease
Abstract Background: Individuals with Duffy-null phenotype have lower circulating neutrophils without an increased risk of infection. Duffy-...
Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LINKER-MM2 trial
Abstract Introduction LINVO, a human B-cell maturation antigen (BCMA)xCD3 bispecific antibody, was recently approved for triple-class expose...